# US 2013/0158510 A1 · System and method for treatment of hemorrhagic stroke

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158510 A1
- Document ID: US20130158510A1
- Status: Published application
- Kind: A1
- Application number: 13/529,608
- Filed: 2012-06-21
- Published: 2013-06-20
- Earliest claimed: 2011-06-30
- Assignees: InCube Labs, LLC
- Inventors: Mir Imran
- Web page: https://patentgrep.com/patent/US20130158510A1

## CPC

- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61B 17/12031: {complete occlusion}
- A61B 17/12113: {within an aneurysm}
- A61B 17/1214: {Coils or wires}
- A61B 17/12186: {liquid materials adapted to be injected}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61M 25/0043: {characterised by structural features}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61M 2025/0042: {Microcatheters, cannula or the like having outside diameters around 1 mm or less}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Embodiments of the invention provide apparatus, methods and systems for delivering treatments and for medications to the site of an aneurysm (SOA). One embodiment of a method comprises delivering a neural growth stimulating factor (NGSF) to the site of the aneurysm to grow new nerve cells and/or stimulate the regeneration of damaged nerve cells. The NGSF may be delivered in a carrier such as a gel which can be selected to allow for long term delivery of the NGSF to the SOA. In many embodiments, the NGSF may be delivered to the SOA using a micro-catheter based system which includes a microcatheter that can be advanced in the cerebral vasculature. The microcatheter may also be used to delivery occlusive element to the SOA such as occlusive coils or balloon which promote clotting and reduce bleeding at the SOA and together with the carrier allow for long term release of NGSF.

## Claims

### Claim 1

A method for treating a cerebral aneurysm, the method comprising:
delivering a neural growth stimulating agent to the aneurysm.

### Claim 2 (depends on 1)

A method as in claim 1, wherein the neural growth stimulating agent comprises a member of the transforming growth factor-β family.

### Claim 3 (depends on 1)

A method as in claim 1, wherein the neural growth stimulating factor comprises glial cell derived neurotrophic factor (GDNF).

### Claim 4 (depends on 1)

A method as in claim 1, wherein the neural growth stimulating factor is present in a carrier when delivered to the aneurysm.

### Claim 5 (depends on 4)

A method as in claim 4, wherein the carrier displays thixotropic behavior when delivered to the aneurysm.

### Claim 6 (depends on 1)

A method as in claim 1, wherein the carrier comprises a gel.

### Claim 7 (depends on 1)

A method as in claim 1, wherein the carrier is saturated with oxygen.

### Claim 8 (depends on 1)

A method claim 1, further comprising delivering occlusive elements to the aneurysm.

### Claim 9 (depends on 8)

A method as in claim 8, wherein the occlusive elements are delivered together with the neural growth stimulating agent.

### Claim 10 (depends on 9)

A method as in claim 9, wherein the occlusive elements comprise coils or balloons.

### Claim 11 (depends on 9)

A method as in claim 9, wherein the occlusive elements promote clotting in the aneurysmal sac.

### Claim 12 (depends on 9)

A method as in claim 9, wherein the occlusive elements result in at least partial filling of the aneurysmal sac.

### Claim 13 (depends on 1)

A method as in claim 1, further comprising delivering an anti-inflammatory agent to the aneurysm.

### Claim 14 (depends on 13)

A method as in claim 13, wherein the anti-inflammatory agent comprises dexamethasone.

### Claim 15 (depends on 13)

A method as in claim 13, wherein the anti-inflammatory agent is delivered to the aneurysm together with the neural growth stimulating growth factor.

### Claim 16 (depends on 1)

A method as in claim 1, further comprising delivering a neural protective agent to the aneurysm.

### Claim 17 (depends on 1)

A method as in claim 1, further comprising delivering a calcium channel blocker to the aneurysm.

### Claim 18

A system for delivering a neural growth factor to a cerebral aneurysm, the system comprising:
a microcatheter having a deliver lumen, said microcatheter adapted to be advanced to the site of the aneurysm in the cerebral vasculature, and
a source of neural growth factor suitable for delivering through the microcatheter to the aneurysm.

### Claim 19 (depends on 18)

A system as in claim 18, wherein the neural growth stimulating factor comprises glial cell derived neurotrophic factor (GDNF).

### Claim 20 (depends on 18)

A system as in claim 18, wherein the neural growth stimulating factor is present in a carrier when delivered to the aneurysm.

### Claim 21 (depends on 20)

A system as in claim 20, wherein the carrier displays thixotropic behavior when delivered to the aneurysm.

### Claim 22 (depends on 21)

A system as in claim 21, wherein the carrier comprises a gel.

### Claim 23 (depends on 20)

A system as in claim 20, wherein the carrier is saturated with oxygen.

### Claim 24 (depends on 18)

A system as in claim 18, further comprising occlusive elements configured to be positioned in the aneurysm and mechanically promote clotting within a sac of the aneurysm.

### Claim 25 (depends on 24)

A system as in claim 24, wherein the occlusive elements comprise coils or balloons.

### Claim 26 (depends on 18)

A system as in claim 18, further comprising an anti-inflammatory agent to the aneurysm in the source of neural growth factor.

### Claim 27 (depends on 26)

A system as in claim 26, wherein the anti-inflammatory agent comprises dexamethasone.

### Claim 28 (depends on 24)

A system as claim 24, further comprising a neural protective agent in the source of neural growth factor.

### Claim 29 (depends on 24)

A system as in claim 24, further comprising a calcium channel blocker in the source of neural growth factor.
